JAK Inhibitors · Autoimmune Diseases
The autoimmune disease need
A targeted route through complex immune signaling.
Autoimmune diseases are often driven by dysregulated cytokine signaling. Current therapies can leave significant gaps in efficacy, selectivity, and tolerability.
Vyome’s JAK franchise is designed around selective pathway inhibition
Selective JAK 1/3 inhibitor asset for cytokine-driven inflammatory signaling
Selective JAK 1 inhibitor asset for targeted immune-pathway modulation
Preclinical program
The JAK program is designed to bring differentiated selectivity to a broad set of autoimmune and inflammatory disease opportunities.
Selective JAK 1/3 inhibitor
A preclinical asset designed to address inflammatory signaling through JAK 1/3 selectivity.
Selective JAK 1 inhibitor
A complementary preclinical asset focused on selective JAK 1 pathway modulation.
Two distinct assets
A dual-asset approach supports program flexibility across disease settings.
Originator expertise
The program originated with Impetis Biosciences Limited, a TATA Enterprise.
Program outlook
Building a differentiated immunology franchise.
Vyome is advancing its JAK inhibitor programs to address autoimmune disease opportunities with selective, purpose-built assets.
Autoimmune disease opportunity
Advancing
Preclinical programs in progress
View the full pipeline
